Jun. 18 at 9:30 PM
$GCTS Existing 75M > 120M (45M enlarged)
The stock price rises further if there is only a dilution of
$4 based on 2026 sales of 40M and
$8 / 120M based on 2027 sales of 100M
The expansion to 120M even in the 200M program indicates that management is confident in turning ebidta into a surplus by Q4 2026